Blood mononuclear cell gene expression profiles characterize the oxidant, hemolytic, and inflammatory stress of sickle cell disease.

In sickle cell disease, deoxygenation of intra-erythrocytic hemoglobin S leads to hemoglobin polymerization, erythrocyte rigidity, hemolysis, and microvascular occlusion. Ischemia-reperfusion injury, plasma hemoglobin-mediated nitric oxide consumption, and free radical generation activate systemic inflammatory responses. To characterize the role of circulating leukocytes in sickle cell pathogenesis we performed global transcriptional analysis of blood mononuclear cells from 27 patients in steady-state sickle cell disease (10 patients treated and 17 patients untreated with hydroxyurea) compared with 13 control subjects. We used gender-specific gene expression to validate human microarray experiments. Patients with sickle cell disease demonstrated differential gene expression of 112 genes involved in heme metabolism, cell-cycle regulation, antioxidant and stress responses, inflammation, and angiogenesis. Inducible heme oxygenase-1 and downstream proteins biliverdin reductase and p21, a cyclin-dependent kinase, were up-regulated, potentially contributing to phenotypic heterogeneity and absence of atherosclerosis in patients with sickle cell disease despite endothelial dysfunction and vascular inflammation. Hydroxyurea therapy did not significantly affect leukocyte gene expression, suggesting that such therapy has limited direct anti-inflammatory activity beyond leukoreduction. Global transcriptional analysis of circulating leukocytes highlights the intense oxidant and inflammatory nature of steady-state sickle cell disease and provides insight into the broad compensatory responses to vascular injury.

[1]  T. W. Anderson,et al.  An Introduction to Multivariate Statistical Analysis , 1959 .

[2]  N. Bodyak,et al.  Carbon monoxide suppresses arteriosclerotic lesions associated with chronic graft rejection and with balloon injury , 2003, Nature Medicine.

[3]  G. Vercellotti,et al.  Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. , 2000, Blood.

[4]  E. Salido,et al.  Isolation of a new gene from the distal short arm of the human X chromosome that escapes X-inactivation. , 1992, Human molecular genetics.

[5]  H. D. Hochstein,et al.  Dose-related inflammatory effects of intravenous endotoxin in humans: evaluation of a new clinical lot of Escherichia coli O:113 endotoxin. , 1999, The Journal of infectious diseases.

[6]  H. Bunn Pathogenesis and treatment of sickle cell disease. , 1997, The New England journal of medicine.

[7]  S. Taylor,et al.  In vivo production of type 1 cytokines in healthy sickle cell disease patients. , 1999, Journal of the National Medical Association.

[8]  P. Lane Sickle cell disease. , 1996, Pediatric clinics of North America.

[9]  L. Haywood,et al.  Myocardial infarction in sickle cell disease. , 1996, Journal of the National Medical Association.

[10]  M. Maines,et al.  The heme oxygenase system and cellular defense mechanisms. Do HO-1 and HO-2 have different functions? , 2001, Advances in experimental medicine and biology.

[11]  M. Gladwin,et al.  Divergent Nitric Oxide Bioavailability in Men and Women With Sickle Cell Disease , 2003, Circulation.

[12]  T. Arends,et al.  Levels of tumor necrosis factor alpha/cachectin (TNF alpha) in sera from patients with sickle cell disease. , 1993, Acta haematologica.

[13]  D. Page,et al.  Functional coherence of the human Y chromosome. , 1997, Science.

[14]  Ash A. Alizadeh,et al.  Individuality and variation in gene expression patterns in human blood , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[15]  M. Caligiuri,et al.  Interleukin 15: biology and relevance to human disease. , 2001, Blood.

[16]  J. Ingwall,et al.  Cardiac-Specific Expression of Heme Oxygenase-1 Protects Against Ischemia and Reperfusion Injury in Transgenic Mice , 2001, Circulation research.

[17]  R. Hebbel Perspectives series: cell adhesion in vascular biology. Adhesive interactions of sickle erythrocytes with endothelium. , 1997, The Journal of clinical investigation.

[18]  A. Skoultchi,et al.  Manipulating the onset of cell cycle withdrawal in differentiated erythroid cells with cyclin-dependent kinases and inhibitors. , 2000, Blood.

[19]  宁北芳,et al.  疟原虫var基因转换速率变化导致抗原变异[英]/Paul H, Robert P, Christodoulou Z, et al//Proc Natl Acad Sci U S A , 2005 .

[20]  M. Monk,et al.  Regulation of X-Chromosome Inactivation in Development in Mice and Humans , 1998, Microbiology and Molecular Biology Reviews.

[21]  D. Saunders,et al.  Myocardial infarction in sickle cell anemia , 1984, American journal of hematology.

[22]  C. Brugnara,et al.  Hydroxyurea and sickle cell disease: a chance for every patient. , 2003, JAMA.

[23]  James L. Park,et al.  Heme oxygenase-1 protects against vascular constriction and proliferation , 2001, Nature Medicine.

[24]  H. Farber,et al.  Role of free radicals in the pathogenesis of acute chest syndrome in sickle cell disease , 2001, Respiratory research.

[25]  T. Arends,et al.  Levels of Tumor Necrosis Factor α/Cachectin (TNFα) in Sera from Patients with Sickle Cell Disease , 1993 .

[26]  T. Wun,et al.  Activated monocytes and platelet-monocyte aggregates in patients with sickle cell disease. , 2002, Clinical and laboratory haematology.

[27]  O. Platt,et al.  Mortality in sickle cell disease. Life expectancy and risk factors for early death. , 1994, The New England journal of medicine.

[28]  J. Bischof,et al.  Transgenic sickle mice have vascular inflammation. , 2003, Blood.

[29]  Scott T. Miller,et al.  Cerebrovascular accidents in sickle cell disease: rates and risk factors. , 1998, Blood.

[30]  D. Loukopoulos,et al.  Pharmacological induction of fetal hemoglobin in sickle cell disease and beta-thalassemia. , 2001, Seminars in hematology.

[31]  Manfred E. Wolff,et al.  Burger's Medicinal chemistry , 1980 .

[32]  M. Lyon Genetic activity of sex chromosomes in somatic cells of mammals. , 1970, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[33]  H. Croizat Circulating cytokines in sickle cell patients during steady state , 1994, British journal of haematology.

[34]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[35]  R. Warrier,et al.  Tumor necrosis factor alpha in children with sickle cell disease in stable condition. , 1997, Journal of the National Medical Association.

[36]  A. Choi,et al.  Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway , 2000, Nature Medicine.

[37]  J. Grande,et al.  Oxidative stress and induction of heme oxygenase-1 in the kidney in sickle cell disease. , 2001, The American journal of pathology.

[38]  Scott T. Miller,et al.  Silent cerebral infarcts in sickle cell anemia: a risk factor analysis. The Cooperative Study of Sickle Cell Disease. , 1999, Pediatrics.

[39]  Y. Nagashima,et al.  Transfer of heme oxygenase 1 cDNA by a replication-deficient adenovirus enhances interleukin 10 production from alveolar macrophages that attenuates lipopolysaccharide-induced acute lung injury in mice. , 2001, Human gene therapy.

[40]  A. Duits,et al.  Enhanced levels of soluble VCAM-1 in sickle cell patients and their specific increment during vasoocclusive crisis. , 1996, Clinical immunology and immunopathology.

[41]  T. Pearson,et al.  Red blood cells from patients with sickle cell disease exhibit an increased adherence to cultured endothelium pretreated with tumour necrosis factor (TNF) , 1992, British journal of haematology.

[42]  P. Perrotta,et al.  Transcript profiling of human platelets using microarray and serial analysis of gene expression. , 2003, Blood.

[43]  Jenifer L. Breshears Silent Cerebral Infarcts in Sickle Cell Anemia: A Risk Factor Analysis. , 2000 .

[44]  Anja Vogler,et al.  An Introduction to Multivariate Statistical Analysis , 2004 .

[45]  A. Choi,et al.  Protective effects of heme oxygenase-1 in acute lung injury. , 1999, Chest.

[46]  O. Castro,et al.  The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. , 1994, Blood.

[47]  L. Haywood,et al.  Elevated immunoreactive tumor necrosis factor and interleukin-1 in sickle cell disease. , 1992, Journal of the National Medical Association.

[48]  G. Vercellotti,et al.  Reperfusion injury pathophysiology in sickle transgenic mice. , 2000, Blood.

[49]  C. Pegelow,et al.  Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. , 2003, JAMA.

[50]  J. Alam,et al.  Cellular overexpression of heme oxygenase-1 up-regulates p21 and confers resistance to apoptosis. , 2001, Kidney international.

[51]  Solomon H. Snyder,et al.  Biliverdin reductase: A major physiologic cytoprotectant , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[52]  J. Alam,et al.  Heme protein-induced chronic renal inflammation: suppressive effect of induced heme oxygenase-1. , 2001, Kidney international.

[53]  M. Maines,et al.  The heme oxygenase system: a regulator of second messenger gases. , 1997, Annual review of pharmacology and toxicology.

[54]  R. Hebbel Adhesive interactions of sickle erythrocytes with endothelium. , 1997, The Journal of clinical investigation.

[55]  R. Myers,et al.  Gender-Specific Gene Expression in Post-Mortem Human Brain: Localization to Sex Chromosomes , 2004, Neuropsychopharmacology.

[56]  M. Gladwin,et al.  Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. , 2002 .

[57]  A. Monaco,et al.  The UTX gene escapes X inactivation in mice and humans. , 1998, Human molecular genetics.

[58]  F. Rosner,et al.  Myocardial infarction in sickle cell disease. , 2002, Journal of the National Medical Association.

[59]  A. Choi,et al.  Heme oxygenase-1: function, regulation, and implication of a novel stress-inducible protein in oxidant-induced lung injury. , 1996, American journal of respiratory cell and molecular biology.

[60]  R. Hebbel,et al.  Amendment history : Erratum ( September 2000 ) Hypoxia / reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice , 2018 .

[61]  A. Duits,et al.  Cytokines and Soluble Adhesion Molecules in Sickle Cell Anemia Patients during Hydroxyurea Therapy , 1998, Acta Haematologica.

[62]  A. O. Durojaiye,et al.  Acute phase reactants and severity of homozygous sickle cell disease , 1993, Journal of internal medicine.

[63]  E. Hatzimichael,et al.  The role of cytokines in sickle cell disease , 2000, Annals of Hematology.

[64]  H. Farber,et al.  Increased F2 isoprostanes in the acute chest syndrome of sickle cell disease as a marker of oxidative stress. , 2001, American journal of respiratory and critical care medicine.

[65]  Tzong-Shyuan Lee,et al.  Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice , 2002, Nature Medicine.

[66]  A. Schechter,et al.  Inhibition of Sickle Hemoglobin Polymerization as a Basis for Therapeutic Approaches to Sickle‐Cell Anemia , 2003 .

[67]  J. White,et al.  Abnormal adherence of sickle erythrocytes to cultured vascular endothelium: possible mechanism for microvascular occlusion in sickle cell disease. , 1980, The Journal of clinical investigation.

[68]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[69]  B. Setty,et al.  Vascular cell adhesion molecule-1 is involved in mediating hypoxia-induced sickle red blood cell adherence to endothelium: potential role in sickle cell disease. , 1996, Blood.

[70]  J. Raynes,et al.  Is there an acute-phase response in steady-state sickle cell disease? , 1993, The Lancet.

[71]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .